8-K: DiaMedica Reports Q3 2025 Results, Advances Trials

DiaMedica Therapeutics announced its third quarter 2025 financial results and provided updates on its preeclampsia and acute ischemic stroke clinical programs, including progress in patient enrollment and an extended cash runway.

Summary

• DiaMedica Therapeutics reported condensed consolidated financial results for the third quarter ended September 30, 2025.
• The company's cash and short-term investments increased to $55.3 million as of September 30, 2025, up from $44.1 million at December 31, 2024, primarily due to net proceeds from a July private placement.
• DiaMedica anticipates its current cash and short-term investments will fund operations and planned clinical studies into the second half of 2027.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $21.3 million, an increase from $15.6 million for the same period in 2024.
• Research and Development (R&D) expenses rose to $6.4 million for Q3 2025 (from $5.0 million in Q3 2024) and $17.9 million for the nine months ended September 30, 2025 (from $12.6 million in the prior year period), driven by ReMEDy2 trial progress and Preeclampsia Phase 2 IST.
• General and Administrative (G&A) expenses increased to $2.6 million for Q3 2025 (from $1.9 million in Q3 2024) and $7.3 million for the nine months ended September 30, 2025 (from $5.7 million in the prior year period), due to higher share-based compensation, personnel costs, investor relations, patent, and professional fees.
• Net loss for Q3 2025 was $8.6 million (compared to $6.3 million in Q3 2024), and $24.0 million for the nine months ended September 30, 2025 (compared to $16.5 million in the prior year period).
• In Preeclampsia, Part 1a dose escalation cohort of the Phase 2 IST trial is complete, with an expansion cohort now enrolling, and screening for Part 3 (fetal growth restriction) expected to start soon.
• DiaMedica held an in-person pre-IND meeting with the U.S. FDA to discuss plans for a U.S. Phase 2 DM199 study in Preeclampsia.
• Enrollment in the ReMEDy2 Phase 2/3 trial for Acute Ischemic Stroke (AIS) is nearing 50% of the target of 200 patients for the interim analysis, which is expected in 2H 2026.

Sentiment

Score: 7

Explanation: The company demonstrates strong clinical progress in both preeclampsia and acute ischemic stroke programs, including key enrollment milestones and FDA engagement. A significant capital raise has extended the cash runway into 2H 2027, which is crucial for a clinical-stage biotech. While net losses and expenses increased, this is largely attributable to the advancement of these critical clinical trials, which is an expected part of the development cycle for such companies. The extended runway mitigates concerns about increased burn.

Positives

• Cash and short-term investments increased to $55.3 million as of September 30, 2025, providing an anticipated cash runway into the second half of 2027.
• Preeclampsia Phase 2 IST trial (Part 1a) dose escalation cohort is complete, with an expansion cohort now enrolling at the expected therapeutic dose level.
• Screening for Part 3 (fetal growth restriction) of the Preeclampsia Phase 2 IST trial is expected to begin in the coming weeks.
• An in-person pre-IND meeting with the U.S. FDA was held to discuss plans for a U.S. Phase 2 DM199 study in Preeclampsia, indicating progress towards broader clinical development.
• Enrollment in the ReMEDy2 Phase 2/3 trial for Acute Ischemic Stroke is nearing 50% of the target of 200 patients for the interim analysis, demonstrating good trial progress.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $8.6 million from $6.3 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $24.0 million from $16.5 million in the prior year period.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased to $21.3 million from $15.6 million in the prior year period.
• Research and Development (R&D) expenses increased to $6.4 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, reflecting higher costs associated with clinical trial progress and team expansion.
• General and Administrative (G&A) expenses increased to $2.6 million for Q3 2025 and $7.3 million for the nine months ended September 30, 2025, due to increased non-cash share-based compensation, personnel costs, investor relations, patent, and professional fees.

Risks

• Existing preclinical and clinical data from DM199 for preeclampsia may not be predictive of results from ongoing or later clinical trials.
• DiaMedica's ability to develop, obtain an IND for, and ultimately achieve regulatory approval and commercialize DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke.
• Uncertainty regarding the timing of ReMEDy2 trial enrollment, regulatory applications, and related filing and approval timelines.
• The expectation of steady or increased rates of enrollment in the ReMEDy2 trial may not continue as anticipated.
• The possible occurrence of future adverse events or unfavorable results from current or future trials could adversely affect development.
• DiaMedica's ability to conduct successful clinical testing of DM199 within anticipated parameters, including site activations, enrollment numbers, costs, and timeframes.
• The adaptive design of the ReMEDy2 trial means targeted enrollment and other aspects could change based on factors like FDA input and blinded interim analysis.
• The perceived benefits of DM199 over existing treatment options may not materialize.
• Potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs, and worldwide global supply chain shortages on DiaMedica's business and clinical trials.
• Reliance on collaboration with third parties to conduct clinical trials.
• DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals.

Future Outlook

DiaMedica anticipates completing the Preeclampsia Phase 2 IST Part 1a expansion cohort in 1H 2026 and expects to begin screening for Part 3 (fetal growth restriction) in the coming weeks. The interim analysis for the ReMEDy2 Phase 2/3 trial in Acute Ischemic Stroke is expected in 2H 2026. The company plans to provide an update regarding its pre-IND meeting with the FDA for preeclampsia once final meeting minutes are received. Based on current plans, DiaMedica projects its cash and short-term investments will fund operations into the second half of 2027.

Management Comments

• Rick Pauls, President and CEO of DiaMedica, stated, "We are pleased to see the completion of cohort 10 and the initiation of enrollments in the Part 1a expansion cohort in the ongoing Phase 2 investigators sponsored trial (IST) in preeclampsia."
• Rick Pauls also commented, "Regarding our development program for PE in the United States, we believe that we had a productive in-person pre-IND meeting with the FDA and are awaiting minutes from the meeting. We plan to provide an update after we receive the minutes."
• Rick Pauls further noted, "Enrollment in our ReMEDy2 Phase 2/3 trial in acute ischemic stroke continues to progress as we are nearing 50% of our interim target of 200 patients."

Industry Context

na

Stakeholder Impact

• Shareholders: Benefit from extended cash runway and clinical trial progress, but face increased net losses and operational expenses. The recent private placement diluted existing shares, as indicated by the increase in weighted average shares outstanding.
• Employees: Continued operations and expansion of the clinical team suggest job security and growth opportunities.
• Patients: Potential for new treatments for serious ischemic diseases like preeclampsia, fetal growth restriction, and acute ischemic stroke.

Next Steps

• Receive and review minutes from the in-person pre-IND meeting with the FDA regarding DM199 for preeclampsia.
• Provide an update on the FDA meeting after receiving minutes.
• Implement a protocol amendment for Parts 1b and 2 of the Preeclampsia Phase 2 IST trial to refine treatment regimens.
• Begin screening for participants in Part 3 (fetal growth restriction) of the Preeclampsia Phase 2 IST trial in the coming weeks.
• Complete enrollment for the Part 1a expansion cohort in the Preeclampsia Phase 2 IST trial, expected in 1H 2026.
• Continue enrollment in the ReMEDy2 Phase 2/3 trial for Acute Ischemic Stroke, targeting 200 patients for interim analysis.
• Conduct interim analysis for the ReMEDy2 trial, expected in 2H 2026.
• Host a conference call and webcast on November 13, 2025, to discuss business updates and Q3 2025 financial results.

Key Dates

Recommendation

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company with promising drug candidates in active development. The company has made significant clinical progress in its Preeclampsia and Acute Ischemic Stroke programs, including advancing trial phases and engaging with the FDA. A recent capital raise has substantially bolstered its cash position, providing a runway into 2H 2027, which is a critical positive for a company in this stage. However, the company continues to incur significant and increasing net losses and R&D expenses, which is typical for clinical development but warrants careful monitoring. The stock is a 'hold' as the positive clinical advancements and extended financial stability are balanced against the inherent risks of clinical trials and the ongoing operational losses. Investors should await further clinical data, particularly the ReMEDy2 interim analysis in 2H 2026, before making more aggressive investment decisions.

Keywords

DiaMedica Therapeutics, DMAC, Preeclampsia, Fetal Growth Restriction, Acute Ischemic Stroke, DM199, Clinical Trials, Phase 2, ReMEDy2, Biopharmaceutical, Q3 2025 Earnings, SEC Filing, FDA, IND